Pentoxifylline and skin inflammation

Clinical and Experimental Dermatology

Volumn 23, Issue 4, 1998, Pages 168-172

  Bruynzeel, I ^a   Stoof, T J ^a   Willemze, R ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITOR; PENTOXIFYLLINE; UNCLASSIFIED DRUG;

ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; LEUKOCYTE ADHERENCE; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; SKIN INFLAMMATION;

CELL ADHESION; CYTOKINES; DERMATITIS; HUMANS; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS;

EID: 0031736955     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.1998.00316.x     Document Type: Article

References (66)

1. Beavo JA, Reifsnyder DH. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci 1990; 11: 150-155.
2. Nicholson CD, Challiss RAJ, Shahid M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phophodiesterase isoenzymes. Trends Pharmacol Sci 1991; 12: 19-27.
3. Hanifin JM, Chan SC, Cheng JB et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 1996; 107: 51-56.
4. Texeira MM, Rossi AG, Williams TJ, Hellewell PG. Effects of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in the guinea pig. Br J Pharmacol 1994; 112: 332-340.
5. Badger AM, Olivera DL, Esser KM. Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock. Circulatory Shock 1994; 44: 188-195.
6. Banner KH, Page CP. Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma. Eur Resp J 1995; 8: 996-1000.
7. Muller R, Pentoxifylline, a biomedical profile. J Med 1979; 10: 307-329.
8. Samlaska CP, Winfield EA. Pentoxifylline. J Am Acad Dermatol 1994; 30: 603-621.
9. Noel P, Nelson S, Bokulic R et al. Pentoxifylline inhibits lipopolysaccharide-induced serum tumor necrosis factor and mortality. Life Sci 1990; 47: 1023-1029.
10. Schwarz A, Krone C, Trautinger F et al. Pentoxifylline suppresses irritant and contact hypersensitivity reactions. J Invest Dermatol 1993; 101: 549-555.
11. Schwarz T, Schwarz A, Krone C, Luger TA. Pentoxifylline suppresses allergic patch test reactions in humans. Arch Dermatol 1993; 129: 513-514.
12. Noz KC, Korstanje MJ, Vermeer BJ. Ulcerating necrobiosis lipoidica effectively treated with pentoxifylline. Clin Exp Dermatol 1993; 18: 78-79.
13. Calderon MJ, Landa N, Aguirre A, Diaz-Perez JL. Successful treatment of cutaneous PAN with pentoxifylline. Br J Dermatol 1993; 128: 706-707.
14. Wong SS, Holt PJA. Generalized morphoea and primary biliary cirrhosis: a rare association and improvement with oxypentifylline. Clin Exp Dermatol 1992; 17: 371-373.
15. Wahba-Hahav A. Intractable chronic furunculosis: Prevention of recurrences with pentoxifylline. Acta Derm Venereol 1992; 72: 461-462.
16. Pizarro A, Navarro A, Fonseca E. Treatment of recurrent aphthous stomatitis with pentoxifylline. Br J Dermatol 1995; 133: 659-660.
17. Omulecki A, Broniarczyk-Dyla H, Zak-Prelich M, Choczaj-Kukula A. Is pentoxifylline effective in the treatment of psoriasis? J Am Acad Dermatol 1996; 34: 714-715.
18. Gilhar A, Grossman N, Kahanovicz S et al. Antiproliferative effect of pentoxifylline on psoriatic and normal epidermis. Acta Derm Venereol 1996; 76: 437-441.
19. Kano Y, Hirayama K, Shiohara T. Successful treatment of Schamberg's disease with pentoxifylline. J Am Acad Dermatol 1997; 36: 827-830.
20. Ely H. Is pentoxifylline the drug of the decade? J Am Acad Dermatol 1994; 30: 639-642.
21. Barker JNWN, Mitra RS, Griffiths CEM et al. Keratinocytes as initiators of inflammation. Lancet 1991; 337: 211-214.
22. Stoof TJ, Boorsma DM, Nickoloff BJ. Keratinocytes and immunological cytokines. In: Leigh I, Lane B, Watt F, eds. The Keratinocyte Handbook. Cambridge: Cambridge University Press, 1994; 365-99.
23. Stricter RM, Remick DG, Ward PA et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988; 155: 1230-1236.
24. Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signalling pathway. J Exp Med 1990; 172: 391-394.
25. Waage A, Sorensen M, Stordal BF. Effect of pentoxifylline and HWA 138 on production of tumor necrosis and interleukin 6 from monocytes. In: Hakim J, Mandell GL, Novick WJ, eds. Pentoxifylline and Analogues. Effects on Leukocyte Function. Basel, Switzerland: Karger, 1990; 86-90.
26. Doherty GM, Jensen JC, Alexander HR et al. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 1991; 110: 192-198.
27. Endres S, Fulle HJ, Sinha B et al. Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-α and interleukin-1β by human mononuclear cells. Immunol 1991; 72: 56-60.
28. Schandene L, Vandenbussche P, Crusiaux A et al. Differential effects of pentoxifylline on the production of tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) by monocytes and T cells. Immunol 1992; 76: 30-34.
29. Bienvenu J, Coulon L, Barbier M et al. Study of pentoxifylline induced modulation of TNFα and interleukin-6 secretion in healthy and septic patients by the use of an ex-vivo model on whole blood. Nouv Rev Fr Hematol 1992; 34: S65-S67.
30. Rieneck K, Diamant M, Haahr PM et al. In vitro immunomodulatory effects of pentoxifylline. Immunol Lett 1993; 37: 131-138.
31. Thanhauser A, Reiling N, Bohle A et al. Pentoxifylline: a potent inhibitor of IL-2 and IFN-γ biosynthesis and BCG-induced cytotoxicity. Immunol 1993; 80: 151-156.
32. Van Leenen D, van der Poll T, Levi M et al. Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzees. J Immunol 1993; 151: 2318-2325.
33. Neuner P, Klosner G, Schauer K et al. Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunol 1994; 83: 262-267.
34. Van Furth AM, Steenwijk TM, Langermans JA, van Furth R. In vitro effect of dexamethasone, pentoxifylline, and anti-endotoxin monoclonal antibody on the release of proinflammatory mediators by human leukocytes stimulated with Haemophilus influenzae type B. Pediatric Res 1994; 35: 725-728.
35. Bemelmans MH, Abramowica D, Gouma DJ et al. In vivo T cell activation by anti-CD3 monoclonal antibody induces soluble TNF receptor release in mice. Effects of pentoxifyllinc, methyl-prednisolone, anti-TNF, and anti-IFN-gamma antibodies. J Immunol 1994; 153: 499-506.
36. Jewett A, Bonavida B. Pentoxifylline suppresses interleukin-2-mediated activation of immature human natural killer cells by inhibiting endogenous tumor necrosis factor-alpha secretion. J Clin Immunol 1994; 14: 31-38.
37. Sinha B, Semmler J, Eisenhut T et al. Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur J Immunol 1995; 25: 147-153.
38. Verghese MW, McConnell RT, Strickland AB et al. Differential regulation of human monocyte-derived TNF alpha and II,-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. J Pharmacol Exp Therap 1995; 272: 1313-1320.
39. Neuner P, Klosner G, Pourmojib M et al. Pentoxifylline in vivo and in vitro down-regulates the expression of the intercellular adhesion molecule-1 in monocytes. Immunology 1997; 90: 435-439.
40. Schwarz A, Aragane Y, Simon M et al. Pentoxifylline (PTX) suppresses UVB-induced cytokine release by keratinocytes. J Invest Dermatol 1993; 101: 388A.
41. Platzer C, Meisel C, Vogt K et al. Up-regulation of monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs. Internat Immunol 1995; 7: 517-523.
42. Adams DH, Shaw S. Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet 1994; 343: 831-836.
43. Groves RW, Allen MH, Ross EL et al. Tumour necrosis factor alpha is pro-inflammatory in normal human skin and modulates cutaneous adhesion molecule expression. Br J Dermatol 1995; 132: 345-352.
44. Bertocchi F, Proserpio P, Lampugnani MG, Dejana E. The effect of pentoxifylline on polymorphonuclear cell adhesion to cultured endothelial cells. A preliminary report. In: Mandell GL, Novick WJ, eds. Pentoxifylline and Leukocyte Function. Somerville, New Jersey: Hoechst, 1988; 68-74.
45. Boogaerts MA, Malbrain S, Meeus P et Al. In vitro modulation of normal and diseased human neutrophil function by pentoxilylline. Blut 1990; 61: 60-65
46. Wautier JL, Weill D, Setiadi H et al. Effect of pentoxifylline on monocyte adhesion to endothelial cells in diabetic patients. In: Hakim J, Mandell GL, Novick WJ, eds. Pentoxifylline and Analogues. Effects on Leukocyte Function. Basel, Switzerland: Karger 1990; 42-7.
47. Dosquet C, Weill D, Wautier JL. Molecular mechanism of blood monocyte adhesion to vascular endothelial cells. Nouv Rev Fr Hématol 1992; 34: S55-S59.
48. Franzini E, Sellak H, Babin-Chevaye C et al. Effects of pentoxifylline on the adherence of polymorphonuclear neutrophils to oxidant-stimulated human endothelial cells: involvement of cyclic AMP. J Cardiovasc Pharmacol 1995; 25: S92-S95.
49. Weiss JM, Vanscheidt W, Pilarski KA et al. Pentoxifylline inhibits tumor necrosis factor-α (TNFα)-induced T-lymphoma cell adhesion to endothelioma cells. J Invest Dermatol 1995; 104: 824-828.
50. Bruynzeel I, van der Raaij EMH, Willemze R, Stoof TJ. Pentoxifylline inhibits human T lymphocyte adhesion to dermal endothelial cells. Arch Dermatol Res 1997; 289: 189-193.
51. Bergese SD, Pelletier RP, Ohye RG et al. Treatment of mice with anti-CD3 mAb induces endothelial vascular cell adhesion molecule-1 expression. Transplantation 1994; 57: 711-717.
52. Miller MD, Krangel MS. Biology and biochemistry of the chemokines: A family of chemotactic and inflammatory cytokines. Crit Rev Immunol 1992; 12: 17-46.
53. Zachariae COC. Chemotactic cytokines and inflammation. Biological properties of the lymphocyte and monocyte chemotactic factors ELCF, MCAF and IL-8. Acta Derm Venereol 1991;73:1-30.
54. Larsen CG, Anderson AO, Appella E et al. The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science 1989; 243: 1464-1460.
55. Gillitzer R, Berger R, Mielke V et al. Upper keratinocytes of psoriatic skin lesions express high levels of NAP-1/IL-8 mRNA in situ. J Invest Dermatol 1991; 97: 73-79.
56. Sarris AH, Esgleyes-Ribot T, Crow M et al. Cytokine loops involving interferon-gamma and IP-10, a cytokine chemotactic for CD4+ lymphocytes: an explanation for the epidermotropism of cutaneous T-cell lymphoma? Blood 1995; 86: 651-658.
57. Taub DD, Lloyd AR, Conlon K et al. Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med 1993; 177: 1809-1814.
58. Stoof TJ, van de Brink EN, Willemze R, Boorsma DM. Pentoxifylline (PTX) inhibits interferon-γ (IFN-γ) induced IP-10 mRNA expression on cultured human keratinocytes (KC). J Invest Dermatol 1994, 103: 442A.
59. Stoof TJ, Mitra RS, Sarma Y et al. Keratinocyte activation following T-lymphocyte binding. J Invest Dermatol 1992; 98: 92-95.
60. Simon JC, Cruz PD, Bergstresser PR et al. Phorbol myristate acetate-activated keratinocytes stimulate proliferation of resting peripheral blood mononuclear lymphocytes via a MHC-independent, but protein kinase C- and intercellular adhesion molecule-1-dependent, mechanism. J Immunol 1991; 146: 476-484.
61. Nickoloff BJ, Mitra RS, Green J et al. Accessory function of keratinocytes for superantigens. Dependence on lymphocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction. J Immunol 1993; 150: 2148-2159.
62. Kalish RS. Non-specifically activated human peripheral blood mononuclear cells are cytotoxic for human keratinocytes in vitro. J Immunol 1989; 142: 74-80.
63. Bruynzeel I, van der Raaij EMH, Stoof TJ, Willemze R. Pentoxifylline inhibits T cell adherence to keratinocytes. J Invest Dermatol 1995; 104: 1004-1007.
64. De Fraissinette A, Berman B, Duncan MR, Lefevre L. Effects of pentoxifylline on interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α) induction of intercellular adhesion molecule-1 (ICAM-1) expression on human normal keratinocytes and Langerhans cells. Eur J Dermatol 1992; 2: 265-272.
65. Rao KMK, Currie MS, McCachren SS, Cohen HJ. Pentoxifylline and other methyl xanthines inhibit interleukin-2 receptor expression in human lymphocytes. Cell Immunol 1991; 135: 314-325.
66. Devault GA, Kohan DE, Nelson EW, Holman JM. The effects of oral pentoxifylline on the cytokine release syndrome during inductive OKT3. Transplantation 1994; 57: 532-540.